剂量密集型AC→T方案联合艾迪注射液治疗三阴性乳腺癌的临床观察  

Effect of dose-dense AC→T regimen plus Aidi injection on triple-negative breast cancer

作　　者：陈卓荣[1] 沈三弟[1] 黄湛[1] 雷睿文[1] 刘彦明[2] 

机构地区：[1]粤北人民医院头颈乳腺外科,广东韶关512026 [2]粤北人民医院检验科

出　　处：《中国肿瘤外科杂志》2012年第2期85-87,共3页Chinese Journal of Surgical Oncology

基　　金：韶关市卫生局立项(No.Y12146)

摘　　要：目的观察剂量密集型AC→T方案联合艾迪注射液对三阴性乳腺癌(triple-negative breast cancer,TNBC)新辅助化疗的近期疗效及不良反应。方法将56例TNBC患者分为对照组与治疗组,对照组26例给予剂量密集型AC→T方案治疗,治疗组30例给予剂量密集型AC→T方案联合艾迪注射液治疗,分别对两组患者的近期疗效、骨髓抑制、肝脏及心脏酶谱、KPS评分进行比较。结果两组的近期疗效差异无统计学意义(P>0.05),对照组骨髓抑制程度高于治疗组(P<0.05)。对照组化疗后肝脏及心脏酶谱均明显升高,KPS评分则显著降低(均P<0.05),而治疗组化疗前后无显著变化(均P>0.05)。结论剂量密集型AC→T方案联合艾迪注射液治疗TNBC患者并未提高近期疗效,但能减轻化疗的副反应,提高患者的生活质量。Objective To observe the short-term efficacy and adverse reaction of neoadjuvant chemotherapy with dose-dense AC→T regimen plus Aidi injection to triple-negative breast cancer.Methods 56 cases of breast cancer patients were divided into two groups,control group with dose-dense AC→T regimen （26 cases）,treatment group with dose-dense AC→T regimen plus Aidi injection （30 cases）.The comparison of two groups was performed in short-term efficacy and myelosuppression degree.Liver and myocardial enzymes and Karnofsky performance status（KPS） were compared before and after chemotherapy.Results The difference of short-term efficacy was not significant between treament group and control group（P0.05）,The difference of myelosuppression degree was significant between treament group and control group（P0.05）,liver and myocardial enzyme and KPS in treatment group were superior to those in control group significantly（P0.05）.Conclusions Aidi injection plus dose-dense AC→T regimen don＇t improve the efficacy of neoadjuvant chemotherapy for triple-negative breast cancer,while it reduced the toxicity and promoted life quality of patients significantly.

关 键 词：剂量密集型化疗 三阴性乳腺癌 AC→T方案 艾迪注射液 

分 类 号：R737.9[医药卫生—肿瘤]